Indian scientist designed potential vaccine candidate for new corona virus
Indian Researcher from University of Hyderabad has developed potential vaccine candidate for COVID-19 (novel corona virus). The potential vaccine candidate is active against all the structural and non-structural proteins of COVID-19.
Dr. Seema Mishra, faculty of the Department of Biochemistry, University of Hyderabad has designed potential vaccine candidates, called T cell epitopes, against all the structural and non-structural proteins of COVID-19 for experimental testing.
These vaccine candidates are small coronaviral peptides, molecules which are used by cells to trigger an immune response to destroy cells harboring these viral peptides. Using powerful immunoinformatics approaches with computational softwares, Dr. Seema Mishra has designed these potential epitopes in a way that can be used to vaccinate entire population.
Usually, vaccine discovery takes 15 years but the powerful computational tools helped in quickly enlisting these vaccine candidates in about 10 days. A ranked list of potential candidate vaccines, based on how much effectively they will be used by human cells to stop the virus, has been generated. With no matches present in human protein pool, these coronaviral epitopes pose no cross-reactivity to human cells and hence, the immune response will be against viral proteins and not human proteins.
However, these results have to be investigated experimentally in order to provide conclusive evidence. These results have been disseminated to the scientific community using ChemRxiv preprint platform for urgent experimental assays.
These are the first such studies on COVID-19 vaccine design from India exploring whole coronaviral proteome across structural and non-structural proteins that make up the virus.
Right now, best defense to prevent further novel corona virus infections is social distancing. Vaccination will take some time due to the need for further work on these candidate epitopes. We are hopeful that our computational findings will provide a cost- and time-effective framework for rapid experimental trials towards an effective nCoV vaccine.